New drug aims to tackle obesity and diabetes together

NCT ID NCT07702890

Not yet recruiting Disease control Sponsor: Gubra A/S Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This trial investigates an experimental drug called GUB-UCN2 for people with obesity and type 2 diabetes. The study includes healthy volunteers and those with the conditions, testing the drug alone or alongside standard care. The main goal is to check safety and how the drug behaves in the body over up to 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called GUB-UCN2
What this could lead to: If successful, this could lead to a new treatment option for obesity and type 2 diabetes, potentially helping people manage their weight and blood sugar.
What could go wrong: This is an early-stage trial (Phase 1/2) with a small number of participants, so the drug may not prove safe or effective. Side effects are unknown and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY TYPE 2 DIABETES

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.